Skip to content

C1R suppresses hepatocellular carcinoma cell aggressiveness through promoting HIF-1α degradation and modulating cuproptosis-related protein expression.

Aug 2026 · International Immunopharmacology · Vol 187, pp. 117248 · 0 citations · 21 references
Medicine

TL;DR

A model in which C1R reduces aggressive phenotypes of HCC cells partly through destabilizing HIF-1α and reshaping copper-responsive processes is supported, which supports a model in which C1R reduces aggressive phenotypes of HCC cells partly through destabilizing HIF-1α and reshaping copper-responsive processes.

Abstract

Background

Hepatocellular carcinoma (HCC) frequently develops in the setting of chronic hepatitis B virus (HBV) infection, yet the molecular events shared by HBV-related liver injury and malignant transformation remain incompletely characterized. Recent studies of cuproptosis indicate that copper overload can disturb mitochondrial metabolic programs in tumor cells. This rationale prompted us to examine copper-responsive alterations across chronic HBV-related liver injury and HCC.

Methods

TCGA-LIHC and GSE230397 datasets were analyzed to identify shared differentially expressed genes between HCC and chronic HBV infection. Functional enrichment, ssGSEA, WGCNA, and five machine-learning algorithms were used to screen cuproptosis-associated candidate genes. C1R expression, prognosis, immune infiltration, and immune checkpoint correlations were assessed. Experimental validation was then performed in HCC cell lines by manipulating C1R expression and assessing copper modulation, HIF-1α rescue, intracellular localization, protein expression, oxidative stress, cell motility, HIF-1α stability, proteasome inhibition, and ubiquitination.

Results

The integrated analysis identified 423 genes with concordant dysregulation in the HBV and HCC datasets. These genes were linked to metal ion response, oxidative stress, and copper-associated biological processes. Cuproptosis-related scores were lower in both HCC tissues and HBV-infected liver samples. Integrative WGCNA and machine-learning analyses identified C1R as the only shared cuproptosis associated candidate gene. C1R was downregulated in HCC and associated with survival, immune infiltration, and immune checkpoint molecules. Functionally, C1R overexpression increased FDX1, DLAT, and DLST expression, elevated ROS accumulation, and suppressed HCC cell migration and invasion, whereas C1R knockdown produced opposite effects. Copper chelation with TTM weakened the effects of C1R overexpression, whereas combined elesclomol and CuCl₂ treatment intensified the C1R-associated changes. C1R also lowered HIF-1α levels by the proteasome-sensitive process accompanied by increased HIF-1α ubiquitination. Restoring HIF-1α expression counteracted the effects of C1R on FDX1, DLAT, DLST, invasion, and migration.

Conclusions

C1R is a shared cuproptosis-associated regulator in HBV infection and HCC. The data support a model in which C1R reduces aggressive phenotypes of HCC cells partly through destabilizing HIF-1α and reshaping copper-responsive processes.

View source

Similar papers

Open access Aug 2026

RNF180 loss stabilizes BCAS4 to enhance PD-L1 expression and immune evasion in hepatocellular carcinoma

Summary Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, and the regulation of immune evasion within the tumor microenvironment remains poorly understood. This study shows that breast carcinoma susceptibility protein 4 (BCAS4), not previously studied in HCC, is markedly upregulat...

Ke Ye, Xiu-Peng Cai, Xue-Fan Dong · 0 citations
Aug 2026

FAM117B Promotes Malignant Progression of Hepatocellular Carcinoma by Forming a Bidirectional Regulatory Loop with NAT10 and Activating the JAK-STAT3 Pathway.

The molecular mechanism by which FAM117B promotes HCC progression via forming a bidirectional regulatory loop with NAT10 and activating the JAK-STAT3 signaling pathway through acetylation modification is revealed, providing a novel potential target and theoretical basis for targeted therapy of HCC.

Zhao-Hong Wang, Jian-Feng Fang, Lijun Wu et al. · 0 citations
Open access Sep 2026

MicroRNA-driven regulation of immunosuppressive microenvironment in hepatocellular carcinoma.

We investigated the role of tumor microenvironment (TME) in evolution of liver cirrhosis to hepatocellular carcinoma (HCC). Nonmalignant hepatic tissues, including chronic hepatitis and cirrhosis, retained expression of liver specific miR-122 and hepatocyte nuclear factor 4 (HNF-4) transcription factor and exhibited an...

Gerard J. Nuovo, T. Heineman, E. Tili et al. · 0 citations
Open access Aug 2026

CARS1 as a Prognostic Biomarker and Candidate Therapeutic Vulnerability in Hepatocellular Carcinoma: Insights Into Tumor Progression and the Immune Microenvironment.

BACKGROUND Cysteinyl-tRNA synthetase 1 (CARS1) has been included in ferroptosis-related prognostic signatures, but its clinicopathological relevance, cellular functions, and relationship with the immune microenvironment in hepatocellular carcinoma (HCC) remain incompletely characterized. METHODS Transcriptomic and cl...

Ye-Zhen Tang, Ke-Jun Liu, Zhen-Ya Tan et al. · 0 citations
Open access Sep 2026

DCUN1D5 as a New Biomarker and Regulator of Fatty Acid Metabolism in Hepatocellular Carcinoma

High expression of DCUN1D5 are closely associated with tumor invasion and proliferation and Knockdown of DCUN1D5 was found to inhibit the proliferation, migration, and invasion of HCC cells and increases its free fatty acid accumulation.

Tong Wang, Tian-Run Yang, Tian-Ze Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.